Human epidermal growth factor receptor2 (HER2) overexpression/amplification is associated with high malignancy, rapid disease progression and poor overall survival in breast cancer. The application of anti-HER2 drugs has greatly improved the survival of patients with HER2-positive breast cancer, but drug resistance issues affect the long-term efficacy. The HER2 mutation is considered to be one of the reasons for resistance to anti-HER2 therapy, and there is currently no standard treatment. We report for the first time the detection of HER2 amplification with R157W mutation by second-generation sequencing (NGS) in a 57-year-old hormone receptor-negative, HER2-positive woman with advanced breast cancer who was resistant to multi-line anti-HER2 therapies. She subsequently received pyrotinib combined with capecitabine treatment and achieved partial response. The small-molecule pan-HER family irreversible inhibitor pyrotinib combined with capecitabine has shown a promising effect in the treatment of HER2 mutation-induced resistance, but the molecular mechanism and efficacy need to be further verified.
CITATION STYLE
Qu, Y., Liu, Y., Ding, K., Li, Y., Hong, X., & Zhang, H. (2021). Partial response to pyrotinib plus capecitabine in an advanced breast cancer patient with her2 amplification and r157w mutation after anti-her2 treatment: A case report and literature review. OncoTargets and Therapy, 14, 1581–1588. https://doi.org/10.2147/OTT.S289876
Mendeley helps you to discover research relevant for your work.